Comparative gene expression profiling of placentas from patients with severe pre-eclampsia and unexplained fetal growth restriction
© Nishizawa et al; licensee BioMed Central Ltd. 2011
Received: 5 April 2011
Accepted: 2 August 2011
Published: 2 August 2011
It has been well documented that pre-eclampsia and unexplained fetal growth restriction (FGR) have a common etiological background, but little is known about their linkage at the molecular level. The aim of this study was to further investigate the mechanisms underlying pre-eclampsia and unexplained FGR.
We analyzed differentially expressed genes in placental tissue from severe pre-eclamptic pregnancies (n = 8) and normotensive pregnancies with or (n = 8) without FGR (n = 8) using a microarray method.
A subset of the FGR samples showed a high correlation coefficient overall in the microarray data from the pre-eclampsia samples. Many genes that are known to be up-regulated in pre-eclampsia are also up-regulated in FGR, including the anti-angiogenic factors, FLT1 and ENG, believed to be associated with the onset of maternal symptoms of pre-eclampsia. A total of 62 genes were found to be differentially expressed in both disorders. However, gene set enrichment analysis for these differentially expressed genes further revealed higher expression of TP53-downstream genes in pre-eclampsia compared with FGR. TP53-downstream apoptosis-related genes, such as BCL6 and BAX, were found to be significantly more up-regulated in pre-eclampsia than in FGR, although the caspases are expressed at equivalent levels.
Our current data indicate a common pathophysiology for FGR and pre-eclampsia, leading to an up-regulation of placental anti-angiogenic factors. However, our findings also suggest that it may possibly be the excretion of these factors into the maternal circulation through the TP53-mediated early-stage apoptosis of trophoblasts that leads to the maternal symptoms of pre-eclampsia.
Pre-eclampsia is one of the most common and potentially serious pregnancy-associated disorders and is a principal cause of maternal morbidity, accounting for almost 15-20% of pregnancy-related mortalities . Pre-eclampsia is not a simple complication of pregnancy, but is a syndrome involving multiple organ failure including that of the liver, kidney, lung, and the coagulatory and neural systems. The prognosis for both the mother and fetus in cases of severe pre-eclampsia is poorer than generally expected, particularly in early onset cases (<34 weeks of gestation) . Although these patients are generally treated for prevention of seizures and control of hypertension, the lack of understanding of the precise etiology of pre-eclampsia has hindered the development of preventive and therapeutic measures to treat this disease based on its etiology. Since the risks of maternal multi-organ dysfunction and fetal distress are higher in the early onset forms of this disorder, it has been recommended that the fetus should be delivered during gestational weeks 32-34 in such cases .
There is now an emerging consensus that pre-eclampsia is a complex polygenetic trait in which maternal and fetal genes, as well as environmental factors, are involved. However, the pathogenetic process involves numerous factors such as oxidative stress, endothelial dysfunction, vasoconstriction, metabolic changes, thrombotic disorders and inflammatory responses, and the precise underlying mechanisms have remained elusive [3, 4]. It has also been formally considered, however, that the placenta plays a primary role in the etiology of this disorder. In support of this idea is the observation that patients with pre-eclampsia recover from clinical symptoms of the disorder just after the delivery of the fetus and placenta, that pre-eclampsia occurs in patients with a hydatidiform mole characterized by trophoblast hyperplasia in the absence of any tissues of fetal origin, and also that paternity is a significant risk factor for pre-eclampsia . Several recent lines of evidence have also indicated that placenta-derived anti-angiogenic factors, such as soluble fms-like tyrosine kinase-1 and soluble endoglin, significantly contribute to the onset of pre-eclampsia [6, 7].
Fetal growth restriction (FGR) is another clinical entity that increases the risk of perinatal morbidity and mortality and can result from heterogeneous causes, including maternal, fetal and placental factors. FGR may result from defects in endogenous developmental and growth factors, whereas a placental defect may inhibit the transport of nutrients and oxygen from mother to fetus . Some forms of unexplained FGR have been etiologically linked to pre-eclampsia since they show common pathologic features in the placenta, although this assertion has remained controversial . A failure of trophoblast invasion leading to abnormal shallow vascularity and impaired remodeling of the spiral arteries appears to be a common process behind these disorders . Although pre-eclamptic placentas generally manifest fewer morphological changes than those of FGR cases, the placentas from early-onset cases of pre-eclampsia display substantial villous and vascular abnormalities [11, 12]. In this context, it could be hypothesized that a subset of FGR and early-onset pre-eclampsia cases are likely to share common etiologies, and that the presence or absence of maternal risk factors determines disease manifestation, but this contention remains speculative .
Given the current evidence base, it is of clinical importance to compare the gene expression profiles of pre-eclampsia and FGR to further our understanding of their respective etiologies and aid in the future development of new therapies. In our current study, we have performed such global gene expression profiling via oligonucleotide microarrays of placental tissue from severe pre-eclampsia, unexplained FGR and normal pregnancies.
Clinical parameters of the study groups
(n = 8)
(n = 8)
(n = 8)
Control vs FGR
Control vs PE
FGR vs PE
Maternal age (y)
31.5 ± 6.5a
31.4 ± 3.7
31.0 ± 4.7
Prepregnancy Body mass index
21.4 ± 2.3
19.9 ± 1.9
21.7 ± 3.7
Gestational age at delivery (wks)
38.1 ± 0.8
37.3 ± 1.0
34.4 ± 1.8
Birth weight (g)
2891.5 ± 309.6
1765.4 ± 483.9
1666.6 ± 441.0
Birth weight coefficient
1.007 ± 0.120
0.646 ± 0.151
0.778 ± 0.103
Placental weight (g)
571.4 ± 151.0
329.4 ± 61.3
341.3 ± 59.4
Systolic BP (mmHg)
111.3 ± 11.1
123.3 ± 14.5
160.6 ± 10.0
Diastolic BP (mmHg)
66.9 ± 8.7
77.0 ± 11.9
105.3 ± 9.6
0.76 ± 0.10
1.11 ± 0.32
1.12 ± 0.34
Placental biopsy collection
All of the placental biopsies, both from pre-eclamptic and normotensive pregnancies with or without FGR, were obtained following Caesarean sections. In normotensive cases, Caesarean sections were performed due to previous Caesarean sections. To avoid any effects of labor upon the gene expression profiles of the tissue samples, only placental samples that were obtained from the women who had not undergone labor were included in the study. A central area of chorionic tissue was dissected, and the maternal deciduas and amnionic membranes were removed. We then dissected 1 cm sections of placental villi from the four different central areas between the basal and chorionic plates. After vigorous washing of the maternal blood with saline, tissues were immediately frozen in liquid nitrogen and stored until use.
Total RNA was extracted from the chorionic villous tissues with an RNeasy mini-kit (Qiagen Inc., Valencia, CA) in accordance with the manufacturer's instructions. The quality of the RNA samples was determined by electrophoresis through denaturing agarose gels and staining with ethidium bromide. We measured the intensities of 28S and 18S rRNAs and a higher than 2:1 ratio was considered the benchmark for intact RNA. The RNA was quantified and evaluated for purity by UV spectrophotometry. RNA samples obtained from four different areas of a single placenta were mixed prior to expression analyses. To further assess the quality of the RNA, all specimens were subjected to expression analysis of the housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), using conventional RT-PCR. To test for possible contamination by maternal blood, the expression of a leukocyte-specific gene (leukocyte common antigen; LCA) was also examined using conventional semi-quantitative RT-PCR .
Microarray experiments were performed using the Affymetrix GeneChip system (Affymetrix, Santa Clara, CA). Briefly, approximately 1 μg of each total RNA sample was used for double strand cDNA synthesis. cRNA was synthesized by in vitro transcription followed by sense-strand cDNA synthesis using the Ambion Whole Transcript Expression Kit (Applied Biosystems, Foster City, CA). After fragmentation into ~200 bp strands with uracil DNA glycosylase, synthesized sense-strand cDNAs were end-labeled with biotin, and then hybridized to an Affymetrix Human Exon 1.0 ST Array. Signal intensities were amplified via secondary staining with a biotin-labeled anti-streptavidin antibody followed by phycoerythrin-streptavidin staining. Fluorescent image arrays were obtained using a GeneChip Scanner 3000 (Affymetrix).
Microarray data analyses were performed using Microsoft Excel, Partek Genomics Suite 6.5 (Partek Inc., St. Louis, MO) and Genespring GX11 (Silicon Genetics, Redwood City, CA). All data were subjected to per chip and per gene normalization, quantile normalization and quality control, and a total of 24,805 genes were used for further analysis. Microarray data were deposited in the GEO database with the detailed hybridization information according to the MIAME guidelines and assigned the accession number GSE24129 . To analyze the correlation of microarray data pairs, we used the Pearson's correlation coefficient. In addition, we adopted the non-negative matrix factorization (NMF) method, which is an unsupervised classification algorithm [18, 19]. The NMF method was performed using the NMF package in the R system. K = 2-5 indicates the number of subclasses modeled. To identify specific pathways that may be involved in the progression of pre-eclampsia or FGR, we performed standard gene ontology (GO) analysis using the Gene Spring software. We also performed gene set enrichment analysis (GSEA), a computational method that determines whether defined sets of genes show statistically significant, concordant differences between two biological states [20, 21]. For this analysis we used GSEA v2.06 software from the Broad Institute . Gene sets were downloaded from the Molecular Signatures Database (MSigDB) of this web site. We used the C2 curated catalogue of functional gene sets to select significant gene sets. A false discovery rate (FDR) of less than 0.25 and P values of less than 0.001 were considered significant.
To validate the microarray data for selected genes, we performed quantitative real-time RT-PCR (qRT-PCR) analysis using the Taqman System (Applied Biosystems, Foster City, CA). The Superscript First-strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA) with random primers was used to produce single stranded cDNA templates. A housekeeping gene, ACTB, was used to normalize for mRNA levels because its expression levels among the samples were stable. All RT-PCR reactions were performed in triplicate in a final volume of 25 μl. The cycling conditions used for PCR amplification were 2 min at 50°C, 30 min at 60°C and 1 min at 95°C for RT, followed by 40 cycles of 15 sec at 95°C and 1 min at 60°C. For qRT-PCR, we increased the number of samples in addition to the original 24 samples such that a total of 41 pre-eclampsia, 16 FGR and 45 normotensive pregnancies were analyzed.
Statistical comparisons between groups were performed using the Student's t test and one-way analysis of variance (ANOVA) and differences were considered to be significant at P < 0.05.
To further analyze the correlations for each sample pair, we employed the NMF method to classify the samples based on the overall microarray data. Based on the cophenetic correlation coefficient (coph) calculated for each experiment, K = 2 showed the highest value (coph = 0.9313), indicating that NMF class assignment for K = 2 was the most robust. In addition, whereas all of the normotensive controls were classified as Group 2, most of the pre-eclampsia samples were classified as Group 1. A subset of the FGR samples was also classified as Group 1, suggesting a common pathophysiology with pre-eclampsia for these cases (Figure 1B).
The most highly differentially expressed genes in the pre-eclampsia samples
The most highly differentially expressed genes in the FGR samples
The most highly differentially expressed genes common to pre-eclampsia and FGR
Gene sets enriched in FGR
Gene sets enriched in pre-eclampsia
Microarray analysis of apoptosis-associated genes
(n = 8)
(n = 8)
8.04 ± 0.10
7.93 ± 0.25
8.96 ± 0.15
8.79 ± 0.20
6.44 ± 0.19
6.29 ± 0.38
5.25 ± 0.09
5.50 ± 0.26
8.42 ± 0.16
8.38 ± 0.3
10.07 ± 0.16
10.05 ± 0.27
6.21 ± 0.06
6.21 ± 0.15
7.16 ± 0.10
7.35 ± 0.25
6.59 ± 0.20
6.51 ± 0.26
7.81 ± 0.07
7.72 ± 0.19
7.22 ± 0.21
7.11 ± 0.25
4.71 ± 0.3
4.77 ± 0.36
7.18 ± 0.10
7.17 ± 0.25
6.75 ± 0.14
6.66 ± 0.22
7.18 ± 0.17
7.18 ± 0.19
5.58 ± 0.14
5.47 ± 0.26
7.09 ± 0.23
7.08 ± 0.32
5.97 ± 0.23
6.07 ± 0.29
6.85 ± 0.11
6.82 ± 0.36
4.16 ± 0.14
4.42 ± 0.29
To date, a large body of evidence has accumulated with regards to the global expression profiles of the pre-eclamptic placenta, and several important genes have been identified via this strategy [16, 29, 30]. On the other hand, although there are a comparable number of reports showing microarray analysis for the FGR placenta, these investigations have not been as effective in identifying potentially causative genes for this disease. Previous studies have documented that genes involved in hypoxia or metabolism-related genes are common to the group of differentially expressed genes in the FGR placenta [31–34]. However, these findings may require careful interpretation, since the expression of these genes is often affected by sampling site bias [35, 36]. In addition, although the question of whether pre-eclampsia and FGR share a common etiology is not a long-standing issue, there have been few comparative expression profiles undertaken for these disorders, and the results are not consistent [37, 38].
In our current study, comparative analysis of the global expression profiles of pre-eclampsia and FGR indicate a common pathophysiology. This is based on our findings that 1) pre-eclampsia and a subset of FGR samples show a high correlation coefficient for their overall microarray data and are clustered into the same category, and 2) most of the genes known to be up-regulated in pre-eclampsia were found to be up-regulated in FGR. A possible interpretation might be that pre-eclampsia and a subset of FGR are in fact the same disorder with the same etiology, and that the apparent differences depend on the degree of severity. Alternatively, it is possible that these two disorders are related conditions with the same etiology and differing only by the presence of maternal hypertension.
It was important to then address whether the presence or absence of maternal symptoms determines the phenotypic difference between pre-eclampsia and unexplained FGR. Although standard GO analyses did not reveal specific biological processes or molecular functions, the data from GSEA analyses show that TP53 downstream genes are more highly activated in pre-eclampsia than in FGR. As TP53 itself is not up-regulated at the mRNA level, this activation is likely due to stabilization of the p53 protein, which has a known short half-life . Up-regulated genes in pre-eclampsia also included BAX and BCL6, which are known to regulate apoptosis [40, 41]. A prevailing hypothesis is that trophoblast hypoxia due to abnormal spiral arteries triggers apoptosis leading to the onset of pre-eclampsia . The TP53 pathway may contribute to this process. The current literature does not support the contribution of TP53 to pre-eclampsia but a considerable body of evidence indicates that the apoptosis of trophoblasts itself is increased in the pre-eclamptic placenta [43–45].
Our present data indicate that most of the genes known to be up-regulated in the placenta in pre-eclampsia are also up-regulated in unexplained FGR placentas. These genes include FLT1 and ENG, which encode soluble proteins that are detected in the maternal circulation and serve as anti-angiogenic factors [6, 7]. These data are consistent with previously published findings [46–49]. Although conflicting data have also been reported [50, 51], it might be possible that the FGR samples in these reports might be derived from late-onset cases that are fundamentally different at the molecular level . High levels of these circulating factors are likely to induce maternal systemic endothelial dysfunction. There is little doubt also that the apoptosis of trophoblasts is associated with cell turnover in the placental villi . This apoptotic process halts at an early stage, and dissolution and fusion of the plasma membrane leads to generation of syncytiotrophoblasts, with accompanying microparticles shedding to the maternal circulation [54, 55]. Excess shedding, possibly due to a hypoxia-induced increased turnover of syncytiotrophoblasts, is often observed in the pre-eclamptic placenta and manifests as syncytial knots . It is possible therefore that an up-regulation of the TP53 pathway induces the deportation of microparticles, including high levels of anti-angiogenic factors, and that this might facilitate maternal systemic symptoms in pre-eclampsia [57, 58].
Several reports have now indicated that placentas from FGR pregnancies without pre-eclampsia also manifest increased apoptosis or the up-regulation of TP53 [59–61]. However, the levels of the apoptotic response in FGR appear to be less severe than in pre-eclampsia . In this context, our present data suggest that a subset of unexplained FGR might possibly be pre-eclampsia with mild maternal symptoms that do not fit the currently accepted disease criteria. Our qRT-PCR data showing that TP53-downstream genes are highly up-regulated in pre-eclampsia and in some cases of unexplained FGR lend moderate support to this hypothesis. Hence, in spite of the preliminary nature of the study due to the small sample size, these data warrant further investigation.
We thank the Institute of Bio-System Information, Tohoku Chemical Co. Ltd. for helpful discussions. This study is supported by the JAOG Ogyaa Donation Foundation, by the Hori Information Science Promotion Foundation, and by a grant-in-aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (to H.K.).
- Sibai B, Dekker G, Kupferminc M: Pre-eclampsia. Lancet. 2005, 365: 785-799.View ArticlePubMedGoogle Scholar
- Hall DR, Odendaal HJ, Steyn DW, Grove D: Expectant management of early onset, severe pre-eclampsia: maternal outcome. BJOG. 2000, 107: 1252-1257. 10.1111/j.1471-0528.2000.tb11616.x.View ArticlePubMedGoogle Scholar
- Roberts JM, Cooper DW: Pathogenesis and genetics of pre-eclampsia. Lancet. 2001, 357: 53-56. 10.1016/S0140-6736(00)03577-7.View ArticlePubMedGoogle Scholar
- Woodage T, Venter JC, Broder S: Application of the human genome to obstetrics and gynecology. Clin Obstet Gynecol. 2002, 45: 711-732. 10.1097/00003081-200209000-00014.View ArticlePubMedGoogle Scholar
- Kanter D, Lindheimer MD, Wang E, Borromeo RG, Bousfield E, Karumanchi SA, Stillman IE: Angiogenic dysfunction in molar pregnancy. Am J Obstet Gynecol. 2010, 202: 184.e1-5. 10.1016/j.ajog.2009.09.005.View ArticleGoogle Scholar
- Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA: Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004, 350: 672-683. 10.1056/NEJMoa031884.View ArticlePubMedGoogle Scholar
- Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D'Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA: Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006, 12: 642-649. 10.1038/nm1429.View ArticlePubMedGoogle Scholar
- Cetin I, Alvino G: Intrauterine growth restriction: implications for placental metabolism and transport. A review. Placenta. 2009, 30 (Suppl A): S77-82.View ArticlePubMedGoogle Scholar
- Villar J, Carroli G, Wojdyla D, Abalos E, Giordano D, Ba'aqeel H, Farnot U, Bergsjø P, Bakketeig L, Lumbiganon P, Campodónico L, Al-Mazrou Y, Lindheimer M, Kramer M, World Health Organization Antenatal Care Trial Research Group: Preeclampsia, gestational hypertension and intrauterine growth restriction, related or independent conditions?. Am J Obstet Gynecol. 2006, 194: 921-931. 10.1016/j.ajog.2005.10.813.View ArticlePubMedGoogle Scholar
- Kaufmann P, Black S, Huppertz B: Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod. 2003, 69: 1-7. 10.1095/biolreprod.102.014977.View ArticlePubMedGoogle Scholar
- Mayhew TM, Ohadike C, Baker PN, Crocker IP, Mitchell C, Ong SS: Stereological investigation of placental morphology in pregnancies complicated by pre-eclampsia with and without intrauterine growth restriction. Placenta. 2003, 24: 219-226. 10.1053/plac.2002.0900.View ArticlePubMedGoogle Scholar
- Egbor M, Ansari T, Morris N, Green CJ, Sibbons PD: Morphometric placental villous and vascular abnormalities in early- and late-onset pre-eclampsia with and without fetal growth restriction. BJOG. 2006, 113: 580-589. 10.1111/j.1471-0528.2006.00882.x.View ArticlePubMedGoogle Scholar
- Cross JC: The genetics of pre-eclampsia: a feto-placental or maternal problem?. Clin Genet. 2003, 64: 96-103. 10.1034/j.1399-0004.2003.00127.x.View ArticlePubMedGoogle Scholar
- ACOG Committee on Obstetric Practice: ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Int J Gynaecol Obstet. 2002, 77: 67-75.View ArticleGoogle Scholar
- Ogawa Y, Iwamura T, Kuriya N, Nishida H, Takeuchi H, Takada M, Itabashi K, Imura S, Isobe K: Birth size standards by gestational age for Japanese neonates. Acta Neonat Jap. 1998, 34: 624-632.Google Scholar
- Nishizawa H, Pryor-Koishi K, Kato T, Kowa H, Kurahashi H, Udagawa Y: Microarray analysis of differentially expressed fetal genes in placental tissue derived from early and late onset severe pre-eclampsia. Placenta. 2007, 28: 487-497. 10.1016/j.placenta.2006.05.010.View ArticlePubMedGoogle Scholar
- Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, Aach J, Ansorge W, Ball CA, Causton HC, Gaasterland T, Glenisson P, Holstege FC, Kim IF, Markowitz V, Matese JC, Parkinson H, Robinson A, Sarkans U, Schulze-Kremer S, Stewart J, Taylor R, Vilo J, Vingron M: Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet. 2001, 29: 365-371. 10.1038/ng1201-365.View ArticlePubMedGoogle Scholar
- Kim PM, Tidor B: Subsystem identification through dimensionality reduction of large-scale gene expression data. Genome Res. 2003, 13: 1706-1718. 10.1101/gr.903503.PubMed CentralView ArticlePubMedGoogle Scholar
- Brunet JP, Tamayo P, Golub TR, Mesirov JP: Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci USA. 2004, 101: 4164-4169. 10.1073/pnas.0308531101.PubMed CentralView ArticlePubMedGoogle Scholar
- Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstråle M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC: PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003, 34: 267-273. 10.1038/ng1180.View ArticlePubMedGoogle Scholar
- Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005, 102: 15545-15550. 10.1073/pnas.0506580102.PubMed CentralView ArticlePubMedGoogle Scholar
- Gene Set Enrichment Analysis (GSEA). [http://www.broad.mit.edu/gsea/]
- Muttukrishna S, Knight PG, Groome NP, Redman CW, Ledger WL: Activin A and inhibin A as possible endocrine markers for pre-eclampsia. Lancet. 1997, 349: 1285-1288. 10.1016/S0140-6736(96)09264-1.View ArticlePubMedGoogle Scholar
- Pryor-Koishi K, Nishizawa H, Kato T, Kogo H, Murakami T, Tsuchida K, Kurahashi H, Udagawa Y: Overproduction of the follistatin-related gene protein in the placenta and maternal serum of women with pre-eclampsia. BJOG. 2007, 114: 1128-1137. 10.1111/j.1471-0528.2007.01425.x.View ArticlePubMedGoogle Scholar
- McCarthy JF, Misra DN, Roberts JM: Maternal plasma leptin is increased in preeclampsia and positively correlates with fetal cord concentration. Am J Obstet Gynecol. 1999, 180: 731-736. 10.1016/S0002-9378(99)70280-2.View ArticlePubMedGoogle Scholar
- Nishizawa H, Pryor-Koishi K, Suzuki M, Kato T, Kogo H, Sekiya T, Kurahashi H, Udagawa Y: Increased levels of pregnancy-associated plasma protein-A2 in the serum of pre-eclamptic patients. Mol Hum Reprod. 2008, 14: 595-602. 10.1093/molehr/gan054.View ArticlePubMedGoogle Scholar
- Sartipy P, Loskutoff DJ: Expression profiling identifies genes that continue to respond to insulin in adipocytes made insulin-resistant by treatment with tumor necrosis factor-alpha. J Biol Chem. 2003, 278: 52298-52306. 10.1074/jbc.M306922200.View ArticlePubMedGoogle Scholar
- Kannan K, Amariglio N, Rechavi G, Jakob-Hirsch J, Kela I, Kaminski N, Getz G, Domany E, Givol D: DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene. 2001, 20: 2225-2234. 10.1038/sj.onc.1204319.View ArticlePubMedGoogle Scholar
- Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003, 111: 649-658.PubMed CentralView ArticlePubMedGoogle Scholar
- Enquobahrie DA, Meller M, Rice K, Psaty BM, Siscovick DS, Williams MA: Differential placental gene expression in preeclampsia. Am J Obstet Gynecol. 2008, 199: 566.e1-11. 10.1016/j.ajog.2008.04.020.View ArticleGoogle Scholar
- Roh CR, Budhraja V, Kim HS, Nelson DM, Sadovsky Y: Microarray-based identification of differentially expressed genes in hypoxic term human trophoblasts and in placental villi of pregnancies with growth restricted fetuses. Placenta. 2005, 26: 319-328. 10.1016/j.placenta.2004.06.013.View ArticlePubMedGoogle Scholar
- Okamoto A, Endo H, Kalionis B, Shinya M, Saito M, Nikaido T, Tanaka T: IGFBP1 and Follistatin-like 3 genes are significantly up-regulated in expression profiles of the IUGR placenta. Placenta. 2006, 27: 317-321. 10.1016/j.placenta.2004.12.007.View ArticlePubMedGoogle Scholar
- McCarthy C, Cotter FE, McElwaine S, Twomey A, Mooney EE, Ryan F, Vaughan J: Altered gene expression patterns in intrauterine growth restriction: potential role of hypoxia. Am J Obstet Gynecol. 2007, 196: 70.e1-6. 10.1016/j.ajog.2006.08.027.View ArticleGoogle Scholar
- Struwe E, Berzl G, Schild R, Blessing H, Drexel L, Hauck B, Tzschoppe A, Weidinger M, Sachs M, Scheler C, Schleussner E, Dötsch J: Microarray analysis of placental tissue in intrauterine growth restriction. Clin Endocrinol. 2010, 72: 241-247. 10.1111/j.1365-2265.2009.03659.x.View ArticleGoogle Scholar
- Wyatt SM, Kraus FT, Roh CR, Elchalal U, Nelson DM, Sadovsky Y: The correlation between sampling site and gene expression in the term human placenta. Placenta. 2005, 26: 372-379. 10.1016/j.placenta.2004.07.003.View ArticlePubMedGoogle Scholar
- Tzschoppe AA, Struwe E, Dörr HG, Goecke TW, Beckmann MW, Schild RL, Dötsch J: Differences in gene expression dependent on sampling site in placental tissue of fetuses with intrauterine growth restriction. Placenta. 2010, 31: 178-185. 10.1016/j.placenta.2009.12.002.View ArticlePubMedGoogle Scholar
- Vaiman D, Mondon F, Garcès-Duran A, Mignot TM, Robert B, Rebourcet R, Jammes H, Chelbi ST, Quetin F, Marceau G, Sapin V, Piumi F, Danan JL, Rigourd V, Carbonne B, Ferré F: Hypoxia-activated genes from early placenta are elevated in preeclampsia, but not in Intra-Uterine Growth Retardation. BMC Genomics. 2005, 6: 111-10.1186/1471-2164-6-111.PubMed CentralView ArticlePubMedGoogle Scholar
- Toft JH, Lian IA, Tarca AL, Erez O, Espinoza J, Eide IP, Bjørge L, Draghici S, Romero R, Austgulen R: Whole-genome microarray and targeted analysis of angiogenesis-regulating gene expression (ENG, FLT1, VEGF, PlGF) in placentas from pre-eclamptic and small-for-gestational-age pregnancies. J Matern Fetal Neonatal Med. 2008, 21: 267-273. 10.1080/14767050801924118.View ArticlePubMedGoogle Scholar
- An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV, Neckers LM: Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature. 1998, 392: 405-408. 10.1038/32925.View ArticlePubMedGoogle Scholar
- Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 1994, 9: 1799-1805.PubMedGoogle Scholar
- Albagli-Curiel O: Ambivalent role of BCL6 in cell survival and transformation. Oncogene. 2003, 22: 507-516. 10.1038/sj.onc.1206152.View ArticlePubMedGoogle Scholar
- Levy R, Nelson DM: To be, or not to be, that is the question. Apoptosis in human trophoblast. Placenta. 2000, 21: 1-13. 10.1053/plac.1999.0450.View ArticlePubMedGoogle Scholar
- Jeschke U, Schiessl B, Mylonas I, Kunze S, Kuhn C, Schulze S, Friese K, Mayr D: Expression of the proliferation marker Ki-67 and of p53 tumor protein in trophoblastic tissue of preeclamptic, HELLP, and intrauterine growth-restricted pregnancies. Int J Gynecol Pathol. 2006, 25: 354-360. 10.1097/01.pgp.0000225838.29127.6.View ArticlePubMedGoogle Scholar
- Allaire AD, Ballenger KA, Wells SR, McMahon MJ, Lessey BA: Placental apoptosis in preeclampsia. Obstet Gynecol. 2000, 96: 271-276. 10.1016/S0029-7844(00)00895-4.View ArticlePubMedGoogle Scholar
- Leung DN, Smith SC, To KF, Sahota DS, Baker PN: Increased placental apoptosis in pregnancies complicated by preeclampsia. Am J Obstet Gynecol. 2001, 184: 1249-1250. 10.1067/mob.2001.112906.View ArticlePubMedGoogle Scholar
- Stepan H, Geide A, Faber R: Soluble fms-like tyrosine kinase 1. N Engl J Med. 2004, 351: 2241-2242. 10.1056/NEJM200411183512123.View ArticlePubMedGoogle Scholar
- Stepan H, Krämer T, Faber R: Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction. J Clin Endocrinol Metab. 2007, 92: 2831-2834. 10.1210/jc.2006-2774.View ArticlePubMedGoogle Scholar
- Nevo O, Many A, Xu J, Kingdom J, Piccoli E, Zamudio S, Post M, Bocking A, Todros T, Caniggia I: Placental expression of soluble fms-like tyrosine kinase 1 is increased in singletons and twin pregnancies with intrauterine growth restriction. J Clin Endocrinol Metab. 2008, 93: 285-292.View ArticlePubMedGoogle Scholar
- Yinon Y, Nevo O, Xu J, Many A, Rolfo A, Todros T, Post M, Caniggia I: Severe intrauterine growth restriction pregnancies have increased placental endoglin levels: hypoxic regulation via transforming growth factor-beta 3. Am J Pathol. 2008, 172: 77-85. 10.2353/ajpath.2008.070640.PubMed CentralView ArticlePubMedGoogle Scholar
- Shibata E, Rajakumar A, Powers RW, Larkin RW, Gilmour C, Bodnar LM, Crombleholme WR, Ness RB, Roberts JM, Hubel CA: Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab. 2005, 90: 4895-4903. 10.1210/jc.2004-1955.View ArticlePubMedGoogle Scholar
- Jeyabalan A, McGonigal S, Gilmour C, Hubel CA, Rajakumar A: Circulating and placental endoglin concentrations in pregnancies complicated by intrauterine growth restriction and preeclampsia. Placenta. 2008, 29: 555-563. 10.1016/j.placenta.2008.03.006.PubMed CentralView ArticlePubMedGoogle Scholar
- Rajakumar A, Jeyabalan A, Markovic N, Ness R, Gilmour C, Conrad KP: Placental HIF-1 alpha, HIF-2 alpha, membrane and soluble VEGF receptor-1 proteins are not increased in normotensive pregnancies complicated by late-onset intrauterine growth restriction. Am J Physiol Regul Integr Comp Physiol. 2007, 293: 766-774. 10.1152/ajpregu.00097.2007.View ArticleGoogle Scholar
- Crocker I: Gabor Than Award Lecture 2006: pre-eclampsia and villous trophoblast turnover: perspectives and possibilities. Placenta. 2007, 28: S4-13.View ArticlePubMedGoogle Scholar
- Huppertz B, Frank HG, Kingdom JC, Reister F, Kaufmann P: Villous cytotrophoblast regulation of the syncytial apoptotic cascade in the human placenta. Histochem Cell Biol. 1998, 110: 495-508. 10.1007/s004180050311.View ArticlePubMedGoogle Scholar
- Mayhew TM, Leach L, McGee R, Ismail WW, Myklebust R, Lammiman MJ: Proliferation, differentiation and apoptosis in villous trophoblast at 13-41 weeks of gestation (including observations on annulate lamellae and nuclear pore complexes). Placenta. 1999, 20: 407-422.View ArticlePubMedGoogle Scholar
- Goswami D, Tannetta DS, Magee LA, Fuchisawa A, Redman CW, Sargent IL, von Dadelszen P: Excess syncytiotrophoblast microparticle shedding is a feature of early-onset pre-eclampsia, but not normotensive intrauterine growth restriction. Placenta. 2006, 27: 56-61.View ArticlePubMedGoogle Scholar
- Sargent IL, Germain SJ, Sacks GP, Kumar S, Redman CW: Trophoblast deportation and the maternal inflammatory response in pre-eclampsia. J Reprod Immunol. 2003, 59: 153-160. 10.1016/S0165-0378(03)00044-5.View ArticlePubMedGoogle Scholar
- Heazell AE, Crocker IP: Live and let die - regulation of villous trophoblast apoptosis in normal and abnormal pregnancies. Placenta. 2008, 29: 772-783. 10.1016/j.placenta.2008.07.003.View ArticlePubMedGoogle Scholar
- Smith SC, Baker PN, Symonds EM: Increased placental apoptosis in intrauterine growth restriction. Am J Obstet Gynecol. 1997, 177: 1395-1401. 10.1016/S0002-9378(97)70081-4.View ArticlePubMedGoogle Scholar
- Levy R, Smith SD, Yusuf K, Huettner PC, Kraus FT, Sadovsky Y, Nelson DM: Trophoblast apoptosis from pregnancies complicated by fetal growth restriction is associated with enhanced p53 expression. Am J Obstet Gynecol. 2002, 186: 1056-1061. 10.1067/mob.2002.122250.View ArticlePubMedGoogle Scholar
- Axt R, Kordina AC, Meyberg R, Reitnauer K, Mink D, Schmidt W: Immunohistochemical evaluation of apoptosis in placentae from normal and intrauterine growth-restricted pregnancies. Clin Exp Obstet Gynecol. 1999, 26: 195-198.PubMedGoogle Scholar
- Ishihara N, Matsuo H, Murakoshi H, Laoag-Fernandez JB, Samoto T, Maruo T: Increased apoptosis in the syncytiotrophoblast in human term placentas complicated by either preeclampsia or intrauterine growth retardation. Am J Obstet Gynecol. 2002, 186: 158-166. 10.1067/mob.2002.119176.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.